News

Video

Patritumab Deruxtecan (HER3-DXd) in Patients with EGFR Mutation-Positive Advanced NSCLC

Author(s):

Shirish Gadgeel, MD

Dr. Gadgeel reviews the HERTHENA-Lung01 trial results of the HER3 targeting antibody drug conjugate patritumab deruxtecan in EGFR-positive non-small cell lung cancer.

Related Videos
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Video 13 - "Treatment Considerations in HER2-Mutated NSCLC"
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Video 2 - "Navigating Glioblastoma Imaging: The Patient Journey from Diagnosis to Treatment "
Related Content
Here is your guide to important regulatory approvals made by the FDA in May 2024.
May 31st 2024

OncLive’s May Roundup of Key FDA Approvals in Oncology

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Benjamin J. Solomon, MBBS, PhD
May 31st 2024

Lorlatinib Yields Longest Reported PFS in Advanced ALK+ NSCLC

Hari B. Keshava, MD
October 23rd 2023

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

FDA
May 29th 2024

AFM24 Plus Atezolizumab Wins FDA Fast Track Designation for EGFR Wild-Type NSCLC

Dr Gregory Lubiniecki, vice president, oncology clinical research, Merck Research Laboratories
May 29th 2024

FDA Grants Priority Review to Pembrolizumab Plus Chemotherapy for Advanced Pleural Mesothelioma